Affimed N.V. announced interim safety and efficacy data on its innate cell engager (ICE(R) AFM24 from the ongoing AFM24-102 combination study with atezolizumab, an anti-PD-L1 checkpoint inhibitor, in patients with advanced EGFR-expressing solid tumors. The data update as of December 6(th), 2023, includes 15 patients from the EGFR- wildtype NSCLC cohort with a median of 2 prior lines of therapy. The Company also announced data from the phase 1/2 data study of acimtamig in combination with allogeneic NK in relapsed/refractory Hodgkin Lymphoma patients conducted at the University of Texas MD Anderson Cancer Center.